Abstract
Here, we report a case of multidrug resistance in a patient with chronic hepatitis B. The patient sequentially received lamivudine, adefovir dipivoxil and entecavir, and subsequently developed single-, double- and triple-drug-resistant HBV strains. We consider this case report important because it documents, for the first time, that triple-drug-resistant HBV strains identified in a clinical setting were suppressible by lamivudine add-on adefovir dipivoxil when tenofovir disoproxil fumarate was not available.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenine / analogs & derivatives
-
Adenine / pharmacology
-
Adenine / therapeutic use
-
Adult
-
Antiviral Agents / pharmacology*
-
Antiviral Agents / therapeutic use
-
Drug Resistance, Multiple, Viral* / genetics
-
Drug Therapy, Combination
-
Evolution, Molecular
-
Guanine / analogs & derivatives
-
Guanine / pharmacology
-
Guanine / therapeutic use
-
Hepatitis B virus / drug effects*
-
Hepatitis B virus / genetics
-
Hepatitis B virus / growth & development
-
Hepatitis B, Chronic / drug therapy
-
Hepatitis B, Chronic / genetics
-
Hepatitis B, Chronic / virology*
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / pharmacology
-
Interferon-alpha / therapeutic use
-
Lamivudine / pharmacology
-
Lamivudine / therapeutic use
-
Male
-
Organophosphonates / pharmacology
-
Organophosphonates / therapeutic use
-
Phylogeny
-
Recombinant Proteins
-
Reverse Transcriptase Inhibitors / pharmacology*
-
Reverse Transcriptase Inhibitors / therapeutic use
-
Time Factors
-
Treatment Outcome
Substances
-
Antiviral Agents
-
Interferon alpha-2
-
Interferon-alpha
-
Organophosphonates
-
Recombinant Proteins
-
Reverse Transcriptase Inhibitors
-
Lamivudine
-
entecavir
-
Guanine
-
Adenine
-
adefovir dipivoxil